Online inquiry

IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3182MR)

This product GTTS-WQ3182MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ANPEP gene. The antibody can be applied in Mesothelioma, Hepatocellular carcinoma (HCC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001150.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 290
UniProt ID P15144
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3182MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ349MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ1893MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AGEN2034
GTTS-WQ8461MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HTI-1088
GTTS-WQ16003MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ZW-25
GTTS-WQ2945MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ANB-011
GTTS-WQ14098MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-421
GTTS-WQ14368MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA r-hTBP-1
GTTS-WQ7643MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GEN-1029
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW